Skip to main content

Capsule-Delivered Fecal Microbiota Transplant Is Safe and Well Tolerated in Patients with Ulcerative Colitis

This is a preview of subscription content, access via your institution.


  1. Narula N, Kassam Z, Yuan Y, et al. Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis. Inflamm Bowel Dis. 2017;23:1702–1709.

    Article  PubMed  Google Scholar 

  2. Paramsothy S, Paramsothy R, Rubin DT, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2017;11:1180–1199.

    Article  PubMed  Google Scholar 

  3. Jacob V, Crawford C, Cohen-Mekelburg S, et al. Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis. Inflamm Bowel Dis. 2017;23:903–911.

    Article  PubMed  Google Scholar 

  4. Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–1993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Chin SM, Sauk J, Mahabamunuge J, Kaplan JL, Hohmann EL, Khalili H. Fecal microbiota transplantation for recurrent clostridium difficile infection in patients with inflammatory bowel disease: a single-center experience. Clin Gastroenterol Hepatol. 2017;15:597–599.

    Article  PubMed  Google Scholar 

  6. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:2402–2409.

    Article  PubMed  Google Scholar 

  7. El-Nachef N, Piceno YM, Kassam Z, et al. The role of fecal microbiota transplantation in ulcerative colitis and Crohn’s disease: results from a parallel inflammatory bowel disease cohort study. Gastroenterology. 2017;152:S1008.

    Article  Google Scholar 

  8. Burns L, Dubois N, Smith M, et al. 499 Donor recruitment and eligibility for fecal microbiota transplantation: results from an international public stool bank—gastroenterology. Gastroenterology. 2015;148:S-96–S-97.

    Article  Google Scholar 

  9. Dubois N, Ling K, Osman M, et al. Prospective assessment of donor eligibility for fecal microbiota transplantation at a public stool bank: results from the evaluation of 1387 candidate donors. Open Forum Infect Dis. 2015;.

    Article  Google Scholar 

  10. Kassam Z, Mendolia G, Vo E, et al. Microbial emulsion matrices: a novel method to produce stable, orally available capsules for fecal microbiota transplantation to treatClostridium difficile. Am J Gastroenterol. 2015;110:S568–S569.

    Google Scholar 

  11. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.

    Article  PubMed  Google Scholar 

  12. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389:1218–1228.

    Article  PubMed  Google Scholar 

  13. Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology. 2015;149:109.e6.

    Article  Google Scholar 

  14. Cojocariu C, Stanciu C, Stoica O, et al. Clostridium difficile infection and inflammatory bowel disease. Turk J Gastroenterol. 2014;25:603–610.

    Article  PubMed  Google Scholar 

Download references


Our study was funded by an Anonymous Philanthropic Gift.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Najwa El-Nachef.

Ethics declarations

Conflict of interest

ZK is an employee/shareholder of Finch Therapeutics. No other relevant disclosures or financial conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Adler, E., Tabaa, A., Kassam, Z. et al. Capsule-Delivered Fecal Microbiota Transplant Is Safe and Well Tolerated in Patients with Ulcerative Colitis. Dig Dis Sci 64, 2452–2454 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: